KZIA Stock Alert: Kazia Continues Its Surge on Thursday With 51% Gains

The Kazia Therapeutics clinical trial covered the company's paxalisib as a treatment of glioblastoma. Results from the trial came out positive when compared to the standard of care (SOC). The big news was the increase in the median Overall Survival (OS) period to 14.77 months. For the record, the SOC median OS rate is 13.84 months. A secondary analysis also showed a median OS of 15.54 months. KZIA Stock Movement Today The rally for KZIA stock isn't over yet with the company's shares up another 51.3% as of T ...